TY - JOUR
T1 - Genetic characteristics of Neisseria meningitidis serogroup B strains carried by adolescents living in Milan, Italy
T2 - Implications for vaccine efficacy
AU - Esposito, Susanna
AU - Zampiero, Alberto
AU - Terranova, Leonardo
AU - Montinaro, Valentina
AU - Scala, Alessia
AU - Ansuini, Valentina
AU - Principi, Nicola
PY - 2013
Y1 - 2013
N2 - Before a protein vaccine is introduced into a country, it is essential to evaluate its potential impact and estimate its benefits and costs. The aim of this study was to determine the genetic characteristics of Neisseria meningitidis B (NmB) in the pharyngeal secretions of 1375 healthy adolescents aged 13-19 y living in Milan, Italy, in september 2012, and the possible protection offered by the two currently available NmB protein vaccines. Ninety-one subjects were Nm carriers (6.6%), 29 (31.9%) of whom carried the NmB capsular gene. The 29 identified strains belonged to eight clonal complexes (ccs), the majority of which were in the sT-41/44/Lin.3 cc (n = 11; 37.9%). all of the identified strains harboured fHbp alleles representing a total of 15 sub-variants: the gene for NHBa protein was found in all but three of the studied strains (10.3%) with 13 identified sub-variants. There were 15 porA sub-types, seven of which were identified in just one cc. The findings of this study seem to suggest that both of the protein vaccines proposed for the prevention of invasive disease due to NmB (the 4-protein and the 2-protein products) have a composition that can evoke a theoretically effective antibody response against the meningococcal strains currently carried by adolescents living in Northern Italy. The genetic characteristics of NmB strains can be easily evaluated by means of molecular methods, the results of which can provide an albeit approximate estimate of the degree of protection theoretically provided by the available vaccines, and the possible future need to change their composition.
AB - Before a protein vaccine is introduced into a country, it is essential to evaluate its potential impact and estimate its benefits and costs. The aim of this study was to determine the genetic characteristics of Neisseria meningitidis B (NmB) in the pharyngeal secretions of 1375 healthy adolescents aged 13-19 y living in Milan, Italy, in september 2012, and the possible protection offered by the two currently available NmB protein vaccines. Ninety-one subjects were Nm carriers (6.6%), 29 (31.9%) of whom carried the NmB capsular gene. The 29 identified strains belonged to eight clonal complexes (ccs), the majority of which were in the sT-41/44/Lin.3 cc (n = 11; 37.9%). all of the identified strains harboured fHbp alleles representing a total of 15 sub-variants: the gene for NHBa protein was found in all but three of the studied strains (10.3%) with 13 identified sub-variants. There were 15 porA sub-types, seven of which were identified in just one cc. The findings of this study seem to suggest that both of the protein vaccines proposed for the prevention of invasive disease due to NmB (the 4-protein and the 2-protein products) have a composition that can evoke a theoretically effective antibody response against the meningococcal strains currently carried by adolescents living in Northern Italy. The genetic characteristics of NmB strains can be easily evaluated by means of molecular methods, the results of which can provide an albeit approximate estimate of the degree of protection theoretically provided by the available vaccines, and the possible future need to change their composition.
KW - Invasive bacterial disease
KW - Meningococcal vaccine
KW - Meningococcus B
KW - Meningococcus B vaccine
KW - Neisseria meningitides
UR - http://www.scopus.com/inward/record.url?scp=84887450287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887450287&partnerID=8YFLogxK
U2 - 10.4161/hv.25800
DO - 10.4161/hv.25800
M3 - Article
C2 - 23880917
AN - SCOPUS:84887450287
VL - 9
SP - 2296
EP - 2303
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
SN - 2164-5515
IS - 11
ER -